Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Phase 2 trial of Digoxin completes

Original source

Phase 2 trial of Digoxin completesClinicalTrials.gov · 30 July 2026 (opens in a new tab)

Trial at a glance

Status
Completed
Phase
Phase 2
Intervention
Digoxin (drug)
Enrolment
41 participants (actual)
Site
the United States
Sponsor
Massachusetts General Hospital
Registration
NCT07047209

Compass reports what the trial registry states. A trial being registered, recruiting or completed is not evidence that a treatment works.

This completed Phase 2 interventional study assessed oral digoxin in 41 people with amyotrophic lateral sclerosis at sites in the United States. The registry now records the study as completed, with a completion date of 13 May 2026; results have not been posted.

Why this matters

Completion means this study is no longer recruiting. Results have not yet been posted, so this update provides no findings about the intervention.

Trial updates

Study completed — 30 July 2026

Compass began tracking this trial’s registry record on the date of its first update above. Changes before then are not listed.

Summarised by Compass 30 August 2026 · reported from the United States

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?